antirheumatics/gin diare

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 38 rezilta yo

Kinase inhibitors: a new class of antirheumatic drugs.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The outlook for patients with rheumatoid arthritis has improved significantly over the last three decades with the use of disease-modifying antirheumatic drugs. However, despite the use of methotrexate, cytokine inhibitors, and molecules targeting T and B cells, a percentage of patients do not

Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The toxicity profiles of 7 disease modifying antirheumatic drugs (DMARD) (hydroxychloroquine, intramuscular (im) gold, D-penicillamine, oral gold, methotrexate (MTX), azathioprine and cyclophosphamide) were evaluated in 2,479 patients with rheumatoid arthritis consecutively enrolled at 5 centers in

[Diarrhea].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A 50-year-old female patient complained about watery diarrhea for two weeks. Because of back pain nonsteroidal antirheumatics had been prescribed for months before. The endoscopic and radiologic investigation demonstrated a large gastrocolic fistula due to NSAID-induced gastric ulceration and an

[Current state of treatment and prevention of gastroduodenal side effects of non-steroidal antirheumatic drugs].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In spite of optimized antirheumatic treatment, NSAID-related mucosal lesions ranging to bleeding ulcers occur mainly in the stomach and less frequently in the duodenum. With continued NSAID therapy, overt mucosal lesions can be treated with Omeprazol or H2 blockers. The efficacy of these medications

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP-690,550) or adalimumab monotherapy with placebo for the treatment of active rheumatoid arthritis (RA) in patients with an inadequate response to disease-modifying antirheumatic drugs. METHODS In this

Intestinal microsporidiosis: a hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs?

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Immunosuppressed patients are at risk of microsporidiosis, and this parasitosis has an increased rate of dissemination in this population. Our objective was to evaluate the presence of microsporidiosis and other intestinal parasites in rheumatic disease patients undergoing anti-tumor

Strongyloides stercoralis colitis in a patient positive for human T-cell leukemia virus with rheumatoid arthritis during an anti-rheumatic therapy: a case report

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

An elderly woman with rheumatoid arthritis (RA) presented with a chief complaint of abdominal pain and diarrhea while undergoing treatment with low-dose corticosteroids and abatacept. Endoscopic and histopathological findings revealed manifestations of ulcerative colitis (UC). An intermediate dose

[Antidiarrheal agents: tools and therapeutic agents].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A host of chemically diverse compounds have antidiarrheal potency, however, only a fraction of these agents has gained clinical acceptance. But regardless of their therapeutic status, the effects of these drugs have enhanced our understanding of the physiology and pathophysiology of the intestinal

Low-dose Methotrexate Toxicity in the Setting of Vancomycin-induced Acute Kidney Injury

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Methotrexate is a disease-modifying anti rheumatic drug (DMARD) that is often used in low dosages as the first line drug for rheumatoid arthritis patients. The chemotherapeutic agent works by inhibiting dihydrofolate reductase, and the primary route of clearance of the drug is via the kidneys.

Dietary support with Boswellia resin in canine inflammatory joint and spinal disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

An open multi-centre veterinary clinical trial, comparing conditions before and after treatment with a herbal dietary supplement consisting of a natural resin extract of Boswellia serrata, was conducted by 10 practicing veterinarians in Switzerland. This traditional plant-based supplement is known

[Gastrointestinal side effects in the therapy of rheumatologic diseases].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Antirheumatic drugs may lead to a number of relevant gastrointestinal complications. Symptomatical treatments with glucocorticoids and non steroidal antirheumatic drugs (NSAD) are known to induce gastric or duodenal ulcers, above all under combination therapies. Side effects of DMARD's

[Alopecia areata secondary to the use of leflunomide in patients with rheumatoid arthritis: a case report and literature review].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Rheumatoid arthritis is a chronic, highly disabling autoimmune disease that requires aggressive pharmacological treatment using immunomodulatory drugs grouped under the name of Disease-Modifying Anti-rheumatic Drugs (DMARDs). Leflunomide is one of the most frequently prescribed. This drug, through

[Security of the combined treatment of methotrexate and leflunomide in patients with rheumatoid arthritis].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Rheumatoid Arthritis (RA) is a chronic disease leading to functional impairment and early mortality. Treatment with disease-modifying antirheumatic drugs have shown to achieve disease remission and improves its evolution. The use of combined therapy should have a biological efficacy, no increased

Leflunomide (Arava) is a useful DMARD in Indian (Asian) patients: a clinic-based observational study of 1-year treatment.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Several drug trials, predominantly of Caucasian patients, have demonstrated the therapeutic role of leflunomide (LEF) in the treatment of rheumatoid arthritis (RA). We report an Indian (Asian) experience from a prospective observational study. Two hundred thirty affording patients with moderately

Leflunomide for the treatment of rheumatoid arthritis and autoimmunity.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Leflunomide, a new oral immunomodulatory agent, is effective for the treatment of rheumatoid arthritis. Its mechanism of action in suppressing inflammation is based in its inhibition of dihydroorotate dehydrogenase, an enzyme responsible for de novo synthesis of pyrimidine containing

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye